Turn Therapeutics Redefines Eczema Market with Ex-FDA Chief at the Helm

WESTLAKE VILLAGE, CA – August 12, 2026 – In the high-stakes world of clinical-stage biotechnology, progress is measured not just in data, but in strategic pivots. Turn Therapeutics (Nasdaq: TTRX) just demonstrated a masterclass in the latter, announcing a cascade of updates that signal a significant recalibration of its strategy. Following what the company called one of its most productive quarters, it is expanding a pivotal Phase 2 trial for its lead asset, GX-03, after interim data revealed a promising, and largely overlooked, patient population in atopic dermatitis. Bolstering this clinical momentum is the high-profile appointment of former FDA Commissioner Dr. Stephen Hahn, a move that adds serious regulatory firepower to its arsenal. These developments, combined with an expansion into a second debilitating skin condition, paint a picture of a company aggressively carving out its niche in the competitive dermatology landscape.

The 'Treatment Gap' Strategy

At the core of Turn Therapeutics' recent announcement is a strategic insight gleaned from interim data on its topical eczema cream, GX-03. The ongoing Phase 2 study showed the drug had activity in a broader group of atopic dermatitis patients than first anticipated. Specifically, it proved effective in patients with clinically moderate-to-severe lesions but a low Eczema Area and Severity Index (EASI) score—a metric that measures both the intensity and the bodily spread of the disease.

This identifies a critical “treatment gap.” A patient might suffer from severe, painful eczema on their hands or face, significantly impacting their quality of life, yet be ineligible for advanced systemic therapies because the disease doesn't cover enough of their body to meet a high EASI threshold. “This represents an important and underserved population that may need stronger treatment options but can be ineligible for certain advanced therapies,” stated Bradley Burnam, CEO of Turn Therapeutics.

The data backing this strategic shift is compelling. When the refined enrollment criteria were retroactively applied to the interim patient group, the results were striking. At week four, 61.5% of patients on GX-03 achieved clear or almost clear skin, compared to just 8.3% on the vehicle cream. More impressively, by week eight, 46.2% of those treated with GX-03 achieved complete clearance of their eczema (EASI-100), a high bar for any treatment, versus 8.3% in the control group. Based on this, Turn has expanded the trial to enroll a larger group of 120-135 patients, confident in its ability to demonstrate statistically significant results.

By designing a trial around this specific population, Turn isn't just testing a drug; it's challenging the very framework used to define disease severity. It’s a calculated move to address a clear unmet need, potentially creating a protected market for GX-03 where few competitors are focused.

Bolstering the Bridge to Market

Promising data is only one part of the equation; navigating the complex regulatory pathway to approval is the other. To that end, Turn Therapeutics has made a formidable strategic move by appointing Dr. Stephen M. Hahn as its Executive Clinical and Regulatory Lead. Dr. Hahn, who served as the 24th Commissioner of the U.S. Food and Drug Administration, brings an unparalleled level of experience to the small biotech.

His resume, which includes senior leadership at MD Anderson Cancer Center and CEO-level roles at Flagship Pioneering-backed companies post-FDA, provides Turn with deep insights into clinical development, trial design, and the nuances of regulatory engagement. For a clinical-stage company, securing the guidance of a former FDA chief is a significant de-risking event. It signals to investors and potential partners that the company is serious about building a robust, approvable data package. Dr. Hahn's involvement is not merely advisory; he is directly guiding the clinical and regulatory strategy for GX-03. His personal connection to the disease, having family members who have struggled with atopic dermatitis, adds a layer of personal commitment to the company's mission.

A New Frontier in Inflammatory Skin Disease

Leveraging the scientific rationale behind GX-03, Turn is also expanding its ambitions beyond atopic dermatitis. The company announced plans for a Phase 2a study of GX-03 in hidradenitis suppurativa (HS), a chronic and painful inflammatory skin disease that causes abscesses and tunnels under the skin. The decision is rooted in mechanism. Preclinical data, recently published in the Journal of Dermatological Treatment, shows GX-03 acts on the IL-36 inflammatory pathway.

This pathway is a key driver of inflammation in both atopic dermatitis and, as research increasingly shows, HS. By targeting this upstream inflammatory trigger, GX-03 could offer a novel approach to quieting the auto-inflammatory process in HS. Furthermore, given that HS often involves a microbial component, GX-03's previously demonstrated antimicrobial properties could provide a dual benefit. This plan to develop a single, non-systemic topical therapy that addresses both inflammation and microbial burden could offer a highly differentiated option in a therapeutic area with significant unmet needs and limited effective treatments.

The Financial Engine and its Fuel Gauge

These ambitious clinical and strategic moves are powered by a finite resource: capital. As of June 30, 2026, Turn Therapeutics held $10.3 million in cash, which it estimates provides an operational runway into the third quarter of 2027, enough to complete the newly expanded Phase 2 study. This cash position was bolstered by a recent term loan.

However, the financial statements reveal the classic biotech balancing act. Research and development expenses surged to $0.5 million for the quarter, a five-fold increase from the previous year, reflecting the costs of accelerating clinical development. Consequently, the company's net loss widened significantly to $5.8 million for the quarter. Critically, regulatory filings include a “going concern” warning, a standard but sobering disclosure indicating that the company will need to raise additional capital to fund its long-term operations. This highlights the fundamental reality of the industry: scientific progress is capital-intensive, and Turn Therapeutics is now in a race to translate its promising clinical signals into tangible value before its runway shortens.